FDA enforcement, policy, and rulemaking on compounded semaglutide and tirzepatide — warning letters to telehealth sellers, recalls, and the 503A/503B rules that govern who may legally compound these drugs.
Tracked to date: 1 recall, 30 warning letters, 4 rulemaking actions, and 1 FDA statement involving GLP-1 medications, as of July 17, 2026. Every count links to an FDA primary source above.
FDA Statement
FDA Schedules July 23–24, 2026 Pharmacy Compounding Advisory Committee Meeting on 503A Bulks List
FDA has announced a public meeting of the Pharmacy Compounding Advisory Committee on July 23–24, 2026. According to FDA, the committee will discuss bulk drug substances being considered for inclusion on the 503A Bulks List — the list of substances that state-licensed pharmacies and physicians may use to compound drugs under section 503A of the FD&C Act.
What this meansThe 503A Bulks List governs which bulk substances compounding pharmacies may legally use — the same regulatory framework at the center of the debate over compounded GLP-1s. Meetings like this are where those rules get shaped, which makes the committee's agenda worth following for anyone weighing compounded options and asking a provider on what legal basis its medication is made.
FDA Extends Comment Period on 503B Bulks List Proposal Covering Semaglutide, Tirzepatide, and Liraglutide
On June 26, 2026, FDA extended the comment period for its May 1, 2026 proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List of substances outsourcing facilities may compound from bulk. The new comment deadline is July 30, 2026, under docket FDA-2018-N-3240.
What this meansThe extension keeps the door open for public input on whether outsourcing facilities can compound these GLP-1s from bulk — the underlying proposal is the one to watch.
On June 8, 2026, FDA issued a warning letter to NativeMed after a March 2026 review of nativemed.net, which offers compounded semaglutide and tirzepatide products. FDA says compounded tirzepatide products pictured on the site feature NativeMed’s logo on the label, "suggesting NativeMed is the compounder of those drugs when in fact it is not," and that claims such as "The same active ingredient in Ozempic® and Wegovy®" represent the products as FDA-approved when "Compounded drug products are not FDA-approved." FDA requested a written response within 15 business days.
What this meansA brand name on the vial does not mean that company made the drug — asking who actually compounds and ships a GLP-1 prescription is a basic vetting step for any telehealth service.
On June 8, 2026, FDA issued a warning letter to HydraMed after a March 2026 review of hydramed.com, which offers compounded semaglutide and tirzepatide products. FDA says product images identify "HydraMed" on the label, "suggesting HydraMed is the compounder of those drugs when in fact it is not," and that the site’s claim that products come from an "FDA-approved pharmacy" is "false and misleading" because FDA does not approve or license compounding pharmacies. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
On June 8, 2026, FDA issued a warning letter to Harper Meds after a March 2026 review of harpermeds.com, which offers compounded semaglutide and tirzepatide products. FDA cited product labels identifying "Harper Meds" as if it were the compounder "when in fact it is not," claims like "Same active ingredient as Ozempic™ & Wegovy™," and a claim that products are sourced from "FDA-licensed 503A Outsourcing Facilities" — wording FDA calls "false and misleading" since it grants no such designation. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
On June 8, 2026, FDA issued a warning letter to FitRX, LLC dba AM RX after a March 2026 review of getamrx.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "AM Rx" as if it were the compounder "when in fact it is not," and cites website claims including "Get affordable semaglutide (main ingredient in Ozempic® & Wegovy®) at an affordable price," which FDA says represent unapproved compounded products as FDA-approved. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
On June 8, 2026, FDA issued a warning letter to Altru Telehealth after a March 2026 review of altrutelehealth.com, which offers compounded semaglutide and tirzepatide products. FDA cites claims such as "Compounded semaglutide & tirzepatide offers the same results but at a fraction of the cost of brand names such as Ozempic, Mounjaro & Wegovy" and "[o]ur compounding pharmacies are all FDA approved," which FDA calls "false and misleading" because compounded drugs and compounding pharmacies are not FDA-approved. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
On June 8, 2026, FDA issued a warning letter to Eden Health International Inc. dba Eden after a March 2026 review of tryeden.com, which offers compounded semaglutide and tirzepatide products. FDA says compounded semaglutide and tirzepatide products pictured on the site identify "Eden" on the label, "suggesting Eden is the compounder of those drugs when in fact it is not," and that describing suppliers as "FDA-licensed 503(a) outsourcing facilities" is "false and misleading" because FDA does not license compounding facilities. FDA requested a written response within 15 business days.
What this meansA brand name on the vial does not mean that company made the drug — asking who actually compounds and ships a GLP-1 prescription is a basic vetting step for any telehealth service.
On June 8, 2026, FDA issued a warning letter to Trinity HealthCare Supply, LLC dba altRx after a May 2026 review of altrx.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "altRx" as if it were the compounder "when in fact it is not," and cites claims that "GLP-1s are clinically proven medications" offering "clinically proven weight loss," which FDA says represent unapproved compounded products as evaluated for safety and effectiveness when they have not been. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
On June 8, 2026, FDA issued a warning letter to Amie Health, Inc. dba Amie after a March 2026 review of tryamie.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "amie" as if the company were the compounder "when in fact it is not," and cites claims including "Ozempic, Mounjaro, and Wegovy contain the same active ingredients as our compounded versions" and "All our treatments use FDA-approved active ingredients," which FDA says falsely imply FDA approval. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
On June 8, 2026, FDA issued a warning letter to Thrivelab after a March 2026 review of thrivelab.com, which offers compounded semaglutide products. FDA says pictured compounded semaglutide products identify "thrivelab" on the label, "suggesting Thrivelab is the compounder of those drugs when in fact it is not," and cites claims including "Same active ingredient as Ozempic®" and "clinically proven to work," noting "Compounded drug products are not FDA-approved." FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
On June 8, 2026, FDA issued a warning letter to VivioMD after a March 2026 review of viviomd.com, which offers compounded semaglutide and tirzepatide products. FDA says the compounded semaglutide and tirzepatide products displayed on the site identify "VivioMD" on the pictured label, "suggesting VivioMD is the compounder of those drugs when in fact it is not," which FDA says renders the products misbranded under sections 502(a) and 502(bb) of the FD&C Act. FDA requested a written response within 15 business days.
What this meansA brand name on the vial does not mean that company made the drug — asking who actually compounds and ships a GLP-1 prescription is a basic vetting step for any telehealth service.
On June 8, 2026, FDA issued a warning letter to Glow Medispa, LLC dba Mint Med after a May 2026 review of mintmed.com, which offers compounded semaglutide and tirzepatide products. FDA says the compounded semaglutide and tirzepatide products displayed on the site identify "Mint Med" on the pictured label, "suggesting Mint Med is the compounder of those drugs when in fact it is not," which FDA says renders the products misbranded under sections 502(a) and 502(bb) of the FD&C Act. FDA requested a written response within 15 business days.
What this meansA brand name on the vial does not mean that company made the drug — asking who actually compounds and ships a GLP-1 prescription is a basic vetting step for any telehealth service.
On June 8, 2026, FDA issued a warning letter to Nexlife after a March 2026 review of nexlife.us, which offers compounded semaglutide and tirzepatide products. FDA says the compounded semaglutide and tirzepatide products displayed on the site identify "Nexlife" on the pictured label, "suggesting Nexlife is the compounder of those drugs when in fact it is not," which FDA says renders the products misbranded under sections 502(a) and 502(bb) of the FD&C Act. FDA requested a written response within 15 business days.
What this meansA brand name on the vial does not mean that company made the drug — asking who actually compounds and ships a GLP-1 prescription is a basic vetting step for any telehealth service.
On June 8, 2026, FDA issued a warning letter to Public Health Solution LLC dba DrMedHealth after a March 2026 review of drmedhealth.com, which offers compounded semaglutide and tirzepatide products. FDA cites website claims including "Same active ingredient as Ozempic®" and "Same active ingredient as Mounjaro®," saying such claims "represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
On June 8, 2026, FDA issued a warning letter to D&H Medical Services after a March 2026 review of dhmedicalcenter.com, which offers compounded semaglutide and tirzepatide products. FDA cites claims including "Same ingredient as Ozempic®," "Same ingredient as Rybelsus®," and "Same ingredient as Mounjaro®" for compounded semaglutide and tirzepatide products, saying the claims represent unapproved compounded products as FDA-approved or evaluated for safety and effectiveness when they have not been. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
On June 8, 2026, FDA issued a warning letter to Momentum Health 360 dba Momentum Health after a March 2026 review of momentumhealth360.com, which offers compounded semaglutide, tirzepatide, and liraglutide products. FDA says pictured labels identify "Momentum Health" as if it were the compounder "when in fact it is not," and cites claims including "Same active ingredient in Mounjaro® and Zepbound™" and an "FDA-licensed compounding facility" reference FDA calls "false and misleading." FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
On June 8, 2026, FDA issued a warning letter to Medica Weight Loss after a March 2026 review of medicaweightloss.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "medica weight loss" as if it were the compounder "when in fact it is not," and cites claims including "Tirzepatide is FDA-approved…." and sourcing from an "FDA-approved pharmacy," noting compounded drugs are not FDA-approved and FDA does not approve pharmacies. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
On June 8, 2026, FDA issued a warning letter to Ezra Holdco LLC dba Ezra after a May 2026 review of joinezra.com, which offers compounded semaglutide and tirzepatide products. FDA says the compounded semaglutide and tirzepatide products displayed on the site identify "Ezra" on the pictured label, "suggesting Ezra is the compounder of those drugs when in fact it is not," which FDA says renders the products misbranded under sections 502(a) and 502(bb) of the FD&C Act. FDA requested a written response within 15 business days.
What this meansA brand name on the vial does not mean that company made the drug — asking who actually compounds and ships a GLP-1 prescription is a basic vetting step for any telehealth service.
On June 8, 2026, FDA issued a warning letter to Ready Med after a May 2026 review of readymednow.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "Ready Med" as if it were the compounder "when in fact it is not," and cites claims including "The same active ingredient in Mounjaro® and Zepbound™" and sourcing from an "FDA licensed compounding facility" — wording FDA calls "false and misleading." FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
On June 8, 2026, FDA issued a warning letter to FITISH after a March 2026 review of fitish.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "FITISH" as if it were the compounder "when in fact it is not," and cites claims including "Semaglutide is the active ingredient in ozempic" and "Tirzepatide is the active ingredient in Mounjaro® and Zepbound®," which FDA says represent unapproved compounded products as FDA-approved. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
On June 8, 2026, FDA issued a warning letter to OrderlyMeds after a March 2026 review of orderlymeds.com, which offers compounded semaglutide and tirzepatide products. FDA says compounded semaglutide and tirzepatide products on the site feature OrderlyMeds’ logo on the pictured label, "suggesting OrderlyMeds is the compounder of those drugs when in fact it is not," and that sourcing claims citing an "FDA-licensed pharmacy" are "false and misleading" because FDA grants no such designation. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
On June 8, 2026, FDA issued a warning letter to Roen Health, Inc. dba RoenRx after a March 2026 review of roenrx.com, which offers compounded semaglutide products. FDA says pictured compounded semaglutide products identify "RoenRx" on the label, "suggesting RoenRx is the compounder of those drugs when in fact it is not," and cites claims including "Get affordable semaglutide (main ingredient in Ozempic® & Wegovy®) at an affordable price," noting compounded drugs are not FDA-approved. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
On June 8, 2026, FDA issued a warning letter to Joi and Blokes dba Joi + Blokes after a March 2026 review of joiandblokes.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "Joi + Blokes" as if it were the compounder "when in fact it is not," and cites claims that its products use "the same bioidentical compound as Ozempic and Wegovy," which FDA says represent unapproved compounded products as FDA-approved. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
On June 8, 2026, FDA issued a warning letter to Nova Vascular LLC dba NOVARX after a March 2026 review of novarx.co, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "NOVA RX" as if it were the compounder "when in fact it is not," and cites claims of "access to the same active ingredient found in Ozempic" and sourcing from "FDA Approved Pharmacies" — wording FDA calls "false and misleading" because it does not approve pharmacies. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
On June 8, 2026, FDA issued a warning letter to Clover Meds after a March 2026 review of clovermeds.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "Clover Meds" as if it were the compounder "when in fact it is not," and that the claim its products are sourced from "FDA-licensed Facilities" is "false and misleading," because the FD&C Act establishes no "FDA-approved" or "FDA-licensed" designation for compounding facilities. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
On June 8, 2026, FDA issued a warning letter to Maximus Health, Inc. dba Maximus after a May 2026 review of maximustribe.com, which offers compounded semaglutide and tirzepatide products. FDA cites claims for compounded semaglutide and tirzepatide products including "Clinically studied ingredients," "Proven to lose weight effectively," and sourcing from "FDA approved pharmacies," saying the claims represent unapproved compounded products as FDA-approved and that FDA grants no approval or license to pharmacies. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
FDA Seeks Comment on Information Collection for 503A and 503B Drug Compounding
In a May 26, 2026 Federal Register notice, FDA requested public comment on a proposed information collection covering human drug compounding under sections 503A and 503B of the FD&C Act, as required by the Paperwork Reduction Act. Comments are due July 27, 2026 under docket FDA-2026-N-5128.
On May 12, 2026, FDA issued a warning letter to Fresenius Kabi Compounding, LLC dba Fagron Sterile Services (Canton, MA), a registered 503B outsourcing facility, citing "Adulterated Drug Products." Following an October–November 2025 inspection, FDA noted "serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk." The letter acknowledges a February 5, 2026 voluntary recall of various lots of products produced using certain IV bags, due to lack of sterility assurance.
What this means503B outsourcing facilities compound medications at scale for hospitals, clinics, and telehealth programs — FDA findings at one are a reminder to ask any provider which facility fills its prescriptions and what that facility’s FDA record looks like.
In a May 1, 2026 Federal Register notice, FDA evaluated bulk drug substances nominated for the 503B Bulks List — the list of substances outsourcing facilities may compound from when there is a clinical need. FDA proposes not to include semaglutide, tirzepatide, or liraglutide on the list. Comments were due June 30, 2026 under docket FDA-2018-N-3240 (the deadline was later extended).
What this meansIf finalized, this would mean outsourcing facilities have no clinical-need basis to compound these GLP-1s from bulk outside a shortage — a major development for anyone using compounded GLP-1s, and one more reason to ask a provider exactly where its medication comes from and on what legal basis.
FDA Renews Pharmacy Compounding Advisory Committee Charter Through 2028
In an April 30, 2026 Federal Register notice, FDA announced renewal of the Pharmacy Compounding Advisory Committee for an additional two years, through April 25, 2028. The Commissioner "determined that it is in the public interest to renew" the committee, which advises FDA on compounding matters, including which substances may be compounded.
FDA’s enforcement listings show a Class II recall (D-0471-2026) by Payless Compounders, LLC of Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg and 5 mg (1 mg/mL), in 0.5 mL prescription-only vials. The stated reason is "Lack of Assurance of Sterility." The recall is dated April 22, 2026 and its status is listed as ongoing.
What this meansSterility problems are invisible to the person holding the vial — recalls like this are why it matters to know exactly which pharmacy compounds your prescription and to check its recall history.
On April 7, 2026, FDA issued a warning letter to ProRx LLC (Exton, PA), a registered 503B outsourcing facility, citing "Adulterated Drug Products." After a September 2025 inspection, FDA said products failed to meet 503B conditions and noted "serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk." The letter acknowledges the firm’s October 2025 voluntary recall of a lot of Tirzepatide Injection 27mg/3mL and various lots of Semaglutide Injection multidose vials for lack of sterility assurance.
What this meansOutsourcing facilities like this one supply compounded GLP-1s to clinics and telehealth programs — checking a facility’s FDA inspection and recall history is a concrete way to vet where a prescription actually comes from.
On March 20, 2026, FDA issued a warning letter to RC Outsourcing, LLC (Lowellville, OH), a registered 503B outsourcing facility, citing "Adulterated Drug Products." After an August 2025 inspection, FDA noted "serious deficiencies in your practices for producing drug products, which put patients at risk." The letter acknowledges a September 2025 voluntary recall of four lots of Bevacizumab 1.75 mg/0.07 mL syringes due to a lack of sterility assurance.
What this meansNo GLP-1 products are named here, but 503B facilities anchor the compounding supply chain — FDA’s inspection findings are the public record patients and prescribers can use to vet them.
On February 9, 2026, FDA issued a warning letter to Thrive Health and Wellness, LLC dba Thrive Health Solutions (Englewood, CO), citing "Adulterated Drug Products" after a March–April 2025 inspection found "serious deficiencies in your practices for producing drug products intended or expected to be sterile." FDA identified repackaged products, including "MEGALean (Tirzepatide/Cyanocobalamin) Injections," as unapproved new drugs. The letter acknowledges the firm ceased repackaging sterile products and recalled all repackaged sterile drug products dispensed January 2 through April 18, 2025.
What this meansBranded blends like a tirzepatide-plus-B12 injectable are not FDA-approved products — sterility findings at the firms behind them are exactly why vetting the pharmacy or facility that handles your medication matters.
On February 2, 2026, FDA issued a warning letter to Apollo Care, LLC (Columbia, MO), a registered 503B outsourcing facility, citing "Adulterated Drug Products." After a March 2025 inspection, FDA noted "serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk." The letter acknowledges an April 2025 voluntary recall of a lot of fentanyl/ropivacaine epidural product due to lack of sterility assurance.
What this meansNo GLP-1 products are named, but this is another data point on quality problems across 503B outsourcing facilities — the same class of facility that produces many compounded GLP-1s.